We are live on ! Find out more
SAM

Sectoral Asset Management Portfolio holdings

AUM $121M
1-Year Est. Return 73.47%
This Fund
S&P 500
This Quarter Est. Return
+15.26%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$125M
AUM Growth
-$37.3M
Cap. Flow
-$58.8M
Cap. Flow %
-47.11%
Top 10 Hldgs %
46.07%
Holding
88
New
6
Increased
20
Reduced
44
Closed
14

Top Buys

Rank Stock Value
1
EVMN
Evommune Inc
EVMN
+$11.1M
2
LENZ
LENZ Therapeutics
LENZ
+$1.24M
3
JNJ icon
Johnson & Johnson
JNJ
+$989K
4
COGT icon
Cogent Biosciences
COGT
+$919K
5
AMGN icon
Amgen
AMGN
+$866K

Top Sells

Rank Stock Value
1
GPCR icon
Structure Therapeutics
GPCR
+$8.08M
2
VTYX
Ventyx Biosciences
VTYX
+$7.55M
3
RCUS icon
Arcus Biosciences
RCUS
+$6.35M
4
ANAB icon
AnaptysBio
ANAB
+$5.96M
5
IMTX icon
Immatics
IMTX
+$5.02M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EVMN
1
Evommune Inc
EVMN
$437M
$10.1M 8.08%
+589,005
New +$11.1M
CTNM
2
Contineum Therapeutics
CTNM
$532M
$9.15M 7.34%
800,787
– –
LLY icon
3
Eli Lilly
LLY
$1.05T
$7.82M 6.27%
7,276
-2,100
-22% -$2.01M
SI
4
Shoulder Innovations Inc
SI
$448M
$7.04M 5.64%
492,435
+62,153
+14% +$847K
UNH icon
5
UnitedHealth
UNH
$387B
$4.49M 3.6%
13,595
+50
+0.4% +$16.9K
AMGN icon
6
Amgen
AMGN
$198B
$4.28M 3.43%
13,070
+2,730
+26% +$866K
JNJ icon
7
Johnson & Johnson
JNJ
$609B
$4.2M 3.37%
20,300
+5,000
+33% +$989K
ABBV icon
8
AbbVie
ABBV
$450B
$3.84M 3.08%
16,800
+2,000
+14% +$456K
VRTX icon
9
Vertex Pharmaceuticals
VRTX
$123B
$3.63M 2.91%
8,005
+290
+4% +$125K
ABT icon
10
Abbott
ABT
$175B
$2.94M 2.36%
23,498
+6,300
+37% +$803K
REGN icon
11
Regeneron Pharmaceuticals
REGN
$70.9B
$2.87M 2.3%
3,715
-253
-6% -$172K
ISRG icon
12
Intuitive Surgical
ISRG
$122B
$2.75M 2.2%
4,850
-900
-16% -$479K
BSX icon
13
Boston Scientific
BSX
$65.4B
$2.63M 2.11%
27,626
+5,500
+25% +$539K
ARGX icon
14
argenx
ARGX
$53.8B
$2.43M 1.95%
2,894
-996
-26% -$853K
DHR icon
15
Danaher
DHR
$144B
$2.42M 1.94%
10,575
– –
SYK icon
16
Stryker
SYK
$123B
$2.3M 1.85%
6,550
+2,250
+52% +$820K
TMO icon
17
Thermo Fisher Scientific
TMO
$198B
$2.26M 1.81%
3,900
– –
MRK icon
18
Merck
MRK
$315B
$2.25M 1.81%
21,400
+5,000
+30% +$469K
GILD icon
19
Gilead Sciences
GILD
$167B
$2.2M 1.76%
17,885
-1,665
-9% -$202K
INSM icon
20
Insmed
INSM
$23.5B
$1.95M 1.56%
11,182
-2,243
-17% -$409K
DXCM icon
21
DexCom
DXCM
$29.6B
$1.9M 1.53%
28,700
+8,000
+39% +$517K
VERA icon
22
Vera Therapeutics
VERA
$2.76B
$1.87M 1.5%
36,858
+6,670
+22% +$237K
GPCR icon
23
Structure Therapeutics
GPCR
$3.45B
$1.66M 1.33%
23,872
-198,000
-89% -$8.08M
BNTX icon
24
BioNTech
BNTX
$23.1B
$1.64M 1.31%
17,218
-442
-3% -$44.5K
EW icon
25
Edwards Lifesciences
EW
$49.4B
$1.47M 1.18%
17,250
+2,250
+15% +$185K
1
2 3 4

Similar funds

RIP
Reliant Investment Partners Pinehurst, North Carolina $121M AUM 34.77% 1-Year Est. Return
CCM
Chicago Capital Management Chicago, Illinois $121M AUM 74.36% 1-Year Est. Return
LFWA
LiftPoint Family Wealth Advisors Far Hills, New Jersey $121M AUM
FWA
Fulcrum Wealth Advisors Bellevue, Washington $121M AUM
CF
Conquis Financial Milbrae, California $121M AUM 16.22% 1-Year Est. Return
WIM
Wiregrass Investment Management Thomasville, Georgia $121M AUM
MW
Merited Wealth North Bay Village, Florida $121M AUM
AFC
Avise Financial Cooperative Los Angeles, California $121M AUM

Sectoral Asset Management's Q4 2025 Portfolio in Review

As of Q4 2025, Sectoral Asset Management held 88 positions worth $125M, down 23% from $162M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Sectoral Asset Management withdrew a net $58.8M in Q4 2025, closing 14 positions and reducing 44 holdings. Its most notable exit was AnaptysBio, an estimated $5.96M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier.

Against the trend, Sectoral Asset Management opened a new position in Evommune Inc worth $10.1M.

  • Sectoral Asset Management's largest Q4 2025 buy was Evommune Inc: 589,005 shares worth $10.1M.
  • Sectoral Asset Management added most to Johnson & Johnson in Q4 2025, an estimated $989K increase.
  • Sectoral Asset Management's biggest Q4 2025 reduction was Structure Therapeutics, cutting an estimated $8.08M.
  • Sectoral Asset Management fully exited AnaptysBio in Q4 2025, selling an estimated $5.96M.
  • Sectoral Asset Management's ten largest holdings make up 46% of its $125M portfolio in Q4 2025.
  • Sectoral Asset Management opened 6 new positions and closed 14 in Q4 2025.
  • Sectoral Asset Management's portfolio value fell 23% quarter-over-quarter to $125M.

Based on Sectoral Asset Management's 13F filing for Q4 2025, filed 9 Feb 2026.